|
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): AGM/EGM/AGM/EGM
Corporate News Bad Neustadt a. d. Saale | 7 June 2023
Annual General Meeting approves all agenda items RHÖN-KLINIKUM AG, one of the largest healthcare providers in Germany, today held its 35th Annual General Meeting. The shareholders met virtually. The shareholders of the Company reaffirmed their trust in the Board of Management and the Supervisory Board and gave their approval to all items of the agenda by a large majority. The dividend distribution totals 0.15 euro per no-par value share with dividend entitlement. In his report, Prof. Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM AG, set out the development of the Company and the future challenges ahead. “For 2022 also, RHÖN-KLINIKUM AG can look back on a financially sound, albeit challenging financial year and has made a good start into 2023 – despite difficult conditions in the hospital sector and the economy as a whole. We have implemented many structural measures and further expanded our care offering, above all in the outpatient area.“ RHÖN-KLINIKUM AG’s strategic tasks continue to be the following areas of action: concentrating on its core activities, expanding outpatient care structures, optimising processes, expanding digital structures and offerings, as well as strengthening nursing and medical care.
You can find the 2022 Annual Report at: https://en.rhoen-klinikum-ag.com/annual-report
RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 855,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,100 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
RHÖN-KLINIKUM AG |Head of Corporate Finance, Treasury, Investor Relations and Sustainability RHÖN-KLINIKUM AG | Corporate Communications
07.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | RHÖN-KLINIKUM Aktiengesellschaft |
| Salzburger Leite 1 | |
| 97616 Bad Neustadt a.d.Saale | |
| Germany | |
| Phone: | +49 (0)9771 - 65-0 |
| Fax: | +49 (0)9771 - 97 467 |
| E-mail: | rka@rhoen-klinikum-ag.com |
| Internet: | www.rhoen-klinikum-ag.com |
| ISIN: | DE0007042301 |
| WKN: | 704230 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1651935 |
| End of News | EQS News Service |
|
|
1651935 07.06.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
